Novel Therapies for Diabetic Kidney Disease: Storied Past and Forward Paths
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
IN BRIEF Current therapeutic approaches are only moderately efficacious at preventing the progression of diabetic kidney disease (DKD). As the number of people with DKD continues to rise worldwide, there is an urgent need for novel therapies. A better understanding of the root causes and molecular mechanisms of DKD pathogenesis has enabled the identification of numerous new therapeutic targets, including advanced glycation end products, reactive oxygen species, protein kinase C, and serum amyloid A. Although experimental studies have illustrated the potential of such approaches, challenges in clinical translation remain a barrier in therapeutic development. Advances in preclinical safety and efficacy evaluations and improved delivery systems may aid in clinical translation of novel DKD therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Esposito, K., Nappo, F., Marfella, R., Giugliano, G., Giugliano, F., Ciotola, M., Quagliaro, L., Ceriello, A., & Giugliano, D. (2002) · Circulation · doi:10.1161/01.cir.0000034509.14906.ae · Cited by 1,961 · cited 1×
“ROS also induce signaling cellular cascades, including protein kinase C (PKC) and nuclear factor κB (NFκB), culminating in the expression of numerous proinflammatory and pro-fibrotic genes (23).”
BackgroundKDOQI clinical practice guideline for diabetes and CKD: 2012 update
(2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.005 · Cited by 1,320
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208799 · Cited by 1,319
Combined angiotensin inhibition for the treatment of diabetic nephropathy
Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303154 · Cited by 1,169
Temporal trends in the prevalence of diabetic kidney disease in the United States
de Boer, I. H. (2011) · JAMA · doi:10.1001/jama.2011.861 · Cited by 1,036 · cited 1×
“In parallel with the rising rates of obesity and diabetes in United States, the prevalence of DKD increased 50% between 1998 and 2008 (2).”
BackgroundBardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
Pergola, P. E., Raskin, P., Toto, R. D., Meyer, C. J., Huff, J. W., Grossman, E. B., Krauth, M., Ruiz, S., Audhya, P., Christ-Schmidt, H., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105351 · Cited by 890
Therapeutic Potential of Nrf2 Activators in Streptozotocin-Induced Diabetic Nephropathy
Zheng, H., Whitman, S. A., Wu, W., Wondrak, G. T., Wong, P. K., Fang, D., & Zhang, D. D. (2011) · Diabetes · doi:10.2337/db11-0807 · Cited by 507
Müller, S., Martin, S., Koenig, W., Hanifi-Moghaddam, P., Rathmann, W., Haastert, B., Giani, G., Illig, T., Thorand, B., & Kolb, H. (2002) · Diabetologia · doi:10.1007/s00125-002-0829-2 · Cited by 311
Cited by
The hallmarks of mitochondrial dysfunction in chronic kidney disease
Galvan, D. L., Green, N. H., & Danesh, F. R. (2017) · Kidney International · doi:10.1016/j.kint.2017.05.034 · Cited by 447
Gyurászová, M., Gurecká, R., Bábíčková, J., & Tóthová, Ľ. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/5478708 · Cited by 322
Oxidative stress and the role of redox signalling in chronic kidney disease
Kishi, S., Nagasu, H., Kidokoro, K., & Kashihara, N. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00775-0 · Cited by 267
Diabetes and CKD in the United States population, 2009-2014
Zelnick, L. R., Weiss, N. S., Kestenbaum, B. R., Robinson-Cohen, C., Heagerty, P. J., Tuttle, K., Hall, Y. N., Hirsch, I. B., & de Boer, I. H. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03700417 · Cited by 181
“Moreover, new therapies to prevent and treat diabetic CKD are on the basis of specific mechanisms of kidney injury (25,26).”
BackgroundSelf-citationBack to the future: glomerular hyperfiltration and the diabetic kidney
Tuttle, K. R. (2017) · Diabetes · doi:10.2337/dbi16-0056 · Cited by 108
Self-citation
Metadata
- Authors
- Dieter, B. P., Alicic, R. Z., Meek, R. L., Anderberg, R. J., Cooney, S. K., & Tuttle, K. R.
- Venue
- Diabetes Spectrum
- Publisher
- American Diabetes Association
- Published
- 2015-08-01
- Volume
- 28
- Issue
- 3
- Pages
- 167-174
- ISSN
- 1040-9165 (ISSN-L)
- 1944-7353
- OpenAlex
- W2142954976
- Cited by
- 22
- References
- 10
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel Therapies for Diabetic Kidney Disease: Storied Past and Forward Paths. https://app.cochat.ai/papers/10.2337/diaspect.28.3.167
- The paper
- Dieter, B. P., Alicic, R. Z., Meek, R. L., Anderberg, R. J., Cooney, S. K., & Tuttle, K. R. (2015). Novel Therapies for Diabetic Kidney Disease: Storied Past and Forward Paths. Diabetes Spectrum. https://doi.org/10.2337/diaspect.28.3.167
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.